MNK inhibitors and methods related thereto
US9669031B2 · kind B2 · utility
9Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2016 |
| Grant date | Jun 6, 2017 |
| Priority date | — |
| Expiry date | Jun 21, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds according to Formula (I):or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.